No Cover Image

E-Thesis 133 views

Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer / CAITLIN MAGGS

Swansea University Author: CAITLIN MAGGS

  • E-Thesis under embargo until: 1st October 2026

Abstract

Colorectal cancer (CRC) is the second highest cause of cancer-related deaths globally. First-line treatments include surgical resection, immunotherapy and chemotherapy - whereby 5-fluorouracil (5FU) is a well-established chemotherapeutic agent. Recent studies have implicated specific bacterial speci...

Full description

Published: Swansea, Wales, UK 2023
Institution: Swansea University
Degree level: Master of Research
Degree name: MRes
Supervisor: Facey, Paul.
URI: https://cronfa.swan.ac.uk/Record/cronfa65062
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2023-11-21T15:40:37Z
last_indexed 2023-11-21T15:40:37Z
id cronfa65062
recordtype RisThesis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>65062</id><entry>2023-11-21</entry><title>Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer</title><swanseaauthors><author><sid>40ec3b849333c2ad4d354d9c76cef2d1</sid><firstname>CAITLIN</firstname><surname>MAGGS</surname><name>CAITLIN MAGGS</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-11-21</date><abstract>Colorectal cancer (CRC) is the second highest cause of cancer-related deaths globally. First-line treatments include surgical resection, immunotherapy and chemotherapy - whereby 5-fluorouracil (5FU) is a well-established chemotherapeutic agent. Recent studies have implicated specific bacterial species within the gastrointestinal tract (GIT) microbiome as drivers of tumorigenesis – with these species more-or-less omnipresent in colorectal tumours. Indeed, a higher abundance of pathogenic bacteria, such as Fusobacterium nucleatum, Bacteroides fragilis, Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium and Enterococcus faecalis have been observed in the microbiome of CRC patients. Indeed, these species, which are normally present at low titre in the gut, appear to be significantly overrepresented in CRC patients. Moreover, and perhaps more insidiously, these species have been shown to significantly drive carcinogenesis. Of further interest is the fact that 5FU, the main chemotherapeutic agent used to treat colorectal tumours, also appears to enrich the gut microbiome for these species. Thus, there is a demand for the development of biotherapeutic interventions that are resistant to 5FU and can also ameliorate this dysbiosis. One way that has been suggested is through the use of probiotic supplements. Probiotics are comprised of putative health-promoting bacteria and their ingestion may have the ability to balance the gut microbiome with more ‘healthy’ bacteria. This project will 1. Screen a panel of probiotics to identify strains that are resistant to 5FU, 2. Screen a panel of probiotics to ascertain whether they inhibit CRC-pathogenic bacterial species, 3. Investigate the metabolism preventing the toxic effects and reduced efficacy seen when 5FU is metabolised by certain microbiota members. This will provide insight into whether the probiotic strains have the potential to prevent the occurrence and/or recurrence of CRC via modulation of the CRC gut microbiota.</abstract><type>E-Thesis</type><journal/><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher/><placeOfPublication>Swansea, Wales, UK</placeOfPublication><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic/><keywords>Probiotics, gut microbiota, microbiology, colorectal cancer</keywords><publishedDay>2</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-10-02</publishedDate><doi/><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><supervisor>Facey, Paul.</supervisor><degreelevel>Master of Research</degreelevel><degreename>MRes</degreename><degreesponsorsfunders>KESS2 and Cultech Ltd</degreesponsorsfunders><apcterm/><funders>KESS2 and Cultech Ltd.</funders><projectreference/><lastEdited>2023-11-21T15:41:27.3037934</lastEdited><Created>2023-11-21T15:37:11.1822106</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>CAITLIN</firstname><surname>MAGGS</surname><order>1</order></author></authors><documents><document><filename>Under embargo</filename><originalFilename>Under embargo</originalFilename><uploaded>2023-11-21T15:40:50.3280204</uploaded><type>Output</type><contentLength>2821841</contentLength><contentType>application/pdf</contentType><version>E-Thesis</version><cronfaStatus>true</cronfaStatus><embargoDate>2026-10-01T00:00:00.0000000</embargoDate><documentNotes>Copyright: The Author, Caitlin Maggs, 2023.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling v2 65062 2023-11-21 Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer 40ec3b849333c2ad4d354d9c76cef2d1 CAITLIN MAGGS CAITLIN MAGGS true false 2023-11-21 Colorectal cancer (CRC) is the second highest cause of cancer-related deaths globally. First-line treatments include surgical resection, immunotherapy and chemotherapy - whereby 5-fluorouracil (5FU) is a well-established chemotherapeutic agent. Recent studies have implicated specific bacterial species within the gastrointestinal tract (GIT) microbiome as drivers of tumorigenesis – with these species more-or-less omnipresent in colorectal tumours. Indeed, a higher abundance of pathogenic bacteria, such as Fusobacterium nucleatum, Bacteroides fragilis, Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium and Enterococcus faecalis have been observed in the microbiome of CRC patients. Indeed, these species, which are normally present at low titre in the gut, appear to be significantly overrepresented in CRC patients. Moreover, and perhaps more insidiously, these species have been shown to significantly drive carcinogenesis. Of further interest is the fact that 5FU, the main chemotherapeutic agent used to treat colorectal tumours, also appears to enrich the gut microbiome for these species. Thus, there is a demand for the development of biotherapeutic interventions that are resistant to 5FU and can also ameliorate this dysbiosis. One way that has been suggested is through the use of probiotic supplements. Probiotics are comprised of putative health-promoting bacteria and their ingestion may have the ability to balance the gut microbiome with more ‘healthy’ bacteria. This project will 1. Screen a panel of probiotics to identify strains that are resistant to 5FU, 2. Screen a panel of probiotics to ascertain whether they inhibit CRC-pathogenic bacterial species, 3. Investigate the metabolism preventing the toxic effects and reduced efficacy seen when 5FU is metabolised by certain microbiota members. This will provide insight into whether the probiotic strains have the potential to prevent the occurrence and/or recurrence of CRC via modulation of the CRC gut microbiota. E-Thesis Swansea, Wales, UK Probiotics, gut microbiota, microbiology, colorectal cancer 2 10 2023 2023-10-02 COLLEGE NANME COLLEGE CODE Swansea University Facey, Paul. Master of Research MRes KESS2 and Cultech Ltd KESS2 and Cultech Ltd. 2023-11-21T15:41:27.3037934 2023-11-21T15:37:11.1822106 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science CAITLIN MAGGS 1 Under embargo Under embargo 2023-11-21T15:40:50.3280204 Output 2821841 application/pdf E-Thesis true 2026-10-01T00:00:00.0000000 Copyright: The Author, Caitlin Maggs, 2023. true eng
title Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
spellingShingle Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
CAITLIN MAGGS
title_short Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
title_full Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
title_fullStr Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
title_full_unstemmed Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
title_sort Investigating the potential for probiotic bacteria to be used as biotherapeutic interventions for colorectal cancer
author_id_str_mv 40ec3b849333c2ad4d354d9c76cef2d1
author_id_fullname_str_mv 40ec3b849333c2ad4d354d9c76cef2d1_***_CAITLIN MAGGS
author CAITLIN MAGGS
author2 CAITLIN MAGGS
format E-Thesis
publishDate 2023
institution Swansea University
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 0
active_str 0
description Colorectal cancer (CRC) is the second highest cause of cancer-related deaths globally. First-line treatments include surgical resection, immunotherapy and chemotherapy - whereby 5-fluorouracil (5FU) is a well-established chemotherapeutic agent. Recent studies have implicated specific bacterial species within the gastrointestinal tract (GIT) microbiome as drivers of tumorigenesis – with these species more-or-less omnipresent in colorectal tumours. Indeed, a higher abundance of pathogenic bacteria, such as Fusobacterium nucleatum, Bacteroides fragilis, Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium and Enterococcus faecalis have been observed in the microbiome of CRC patients. Indeed, these species, which are normally present at low titre in the gut, appear to be significantly overrepresented in CRC patients. Moreover, and perhaps more insidiously, these species have been shown to significantly drive carcinogenesis. Of further interest is the fact that 5FU, the main chemotherapeutic agent used to treat colorectal tumours, also appears to enrich the gut microbiome for these species. Thus, there is a demand for the development of biotherapeutic interventions that are resistant to 5FU and can also ameliorate this dysbiosis. One way that has been suggested is through the use of probiotic supplements. Probiotics are comprised of putative health-promoting bacteria and their ingestion may have the ability to balance the gut microbiome with more ‘healthy’ bacteria. This project will 1. Screen a panel of probiotics to identify strains that are resistant to 5FU, 2. Screen a panel of probiotics to ascertain whether they inhibit CRC-pathogenic bacterial species, 3. Investigate the metabolism preventing the toxic effects and reduced efficacy seen when 5FU is metabolised by certain microbiota members. This will provide insight into whether the probiotic strains have the potential to prevent the occurrence and/or recurrence of CRC via modulation of the CRC gut microbiota.
published_date 2023-10-02T15:41:28Z
_version_ 1783188725121941504
score 11.013148

Similar Items